Why Is Viridian Therapeutics Stock Falling Monday?

Core Insights - The REVEAL-1 trial for elegrobart met its primary endpoint, demonstrating a proptosis responder rate of 54% for the Q4W regimen and 63% for the Q8W regimen, compared to 18% for placebo at week 24 [1] - The trial also showed a complete resolution of diplopia in 51% of patients treated with the Q4W regimen versus 16% for placebo, indicating good tolerability of elegrobart [2] Competitive Concerns - William Blair highlighted that the placebo-adjusted proptosis responder rates of 36% (Q4W) and 45% (Q8W) fell short of the expected 51%-73% range, suggesting that the stock price decline may be an overreaction [3] - Analyst Lachlan Hanbury-Brown noted that various factors contributed to the weaker placebo-adjusted change, and the stock is expected to recover as investors analyze the complete dataset [3] Cash Position and Pipeline - The REVEAL-2 study for chronic TED is on track to report topline data in Q2 2026, with a Biologics License Application (BLA) for elegrobart anticipated to be submitted to the FDA in Q1 2027 [4] - The company ended fiscal 2025 with $875 million in cash, which is projected to support its business plans until profitability, especially with expected revenues from elegrobart and veligrotug if approved [5] Competitive Landscape - Viridian Therapeutics shares experienced a significant decline of 38.26%, trading at $16.91 during premarket on Monday [6]